Giessen Pulmonary Hypertension in Lung Cancer Registry

NCT ID: NCT04467333

Last Updated: 2025-04-01

Basic Information

• Recruitment Status: RECRUITING
• Total Enrollment: 500 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2020-06-29
• Study Completion Date: 2040-01-29

Brief Summary

The aim of this study is to investigate the frequency and implications of pulmonary hypertension in lung cancer patients. To do so, data will be collected from all lung cancer patients at the university hospital Giessen. All data will be analyzed for possible hints of pulmonary hypertension as a comorbidity in lung cancer patients. All information will be generated from the regular guidelines based course of treatment and there will be no interventions. This study will serve as a prospective register for all lung cancer patients treated at the university hospital Giessen.

Conditions

Pulmonary Hypertension Due to Lung Diseases and Hypoxia

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Study Groups

All lung cancer patients

There will not be an intervention.

All lung cancer patients.

Intervention Type: OTHER

There will be no specific interventions. All patients will receive guidelines based therapy of lung cancer and their comorbidities.

Interventions

All lung cancer patients.

There will be no specific interventions. All patients will receive guidelines based therapy of lung cancer and their comorbidities.

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• Patient with lung cancer at the University of Giessen lung Cancer Center.

Exclusion Criteria

-

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

University of Giessen

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Bastian Eul, MD

Role: PRINCIPAL_INVESTIGATOR

JLU Giessen

Khodr Tello, MD

Role: PRINCIPAL_INVESTIGATOR

JLU Giessen

Locations

University hospital Giessen

Giessen, Hesse, Germany

Site Status: RECRUITING

Countries

Germany

Central Contacts

Bastian Eul, MD

Role: CONTACT

bastian.eul@innere.med.uni-giessen.de

(+49) 0641/985-42371

Michael John Cekay, MD

Role: CONTACT

michael.cekay@innere.med.uni-giessen.de

Facility Contacts

Bastian Eul, MD

Role: primary

bastian.eul@innere.med.uni-giessen.de

Michael John Cekay, MD

Role: backup

michael.cekay@innere.med.uni-giessen.de

References

Pullamsetti SS, Kojonazarov B, Storn S, Gall H, Salazar Y, Wolf J, Weigert A, El-Nikhely N, Ghofrani HA, Krombach GA, Fink L, Gattenlohner S, Rapp UR, Schermuly RT, Grimminger F, Seeger W, Savai R. Lung cancer-associated pulmonary hypertension: Role of microenvironmental inflammation based on tumor cell-immune cell cross-talk. Sci Transl Med. 2017 Nov 15;9(416):eaai9048. doi: 10.1126/scitranslmed.aai9048.

Reference Type: BACKGROUND

PMID: 29141888 (View on PubMed)

Rako ZA, Cekay M, Yogeswaran A, Yildiz S, Arndt PF, Kremer N, Schafer S, Janetzko P, Thal BR, Mummert CM, Franken JK, Soethe H, Werner HF, Dumitrascu R, Grimminger F, Ghofrani HA, Pullamsetti SS, Seeger W, Naeije R, Savai R, Eul B, Tello K. Echocardiographic Measure of Right Ventricular-Pulmonary Arterial Coupling Predicts Survival in Lung Cancer. Ann Am Thorac Soc. 2025 Jul;22(7):1071-1078. doi: 10.1513/AnnalsATS.202409-949OC.

Reference Type: DERIVED

PMID: 40042816 (View on PubMed)

Other Identifiers

PH in lung cancer registry

Identifier Type: -

Identifier Source: org_study_id